MetLife Investment Management, LLC - ANIKA THERAPEUTICS INC ownership

ANIKA THERAPEUTICS INC's ticker is ANIK and the CUSIP is 035255108. A total of 171 filers reported holding ANIKA THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.38 and the average weighting 0.0%.

Quarter-by-quarter ownership
MetLife Investment Management, LLC ownership history of ANIKA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$143,172
-28.3%
7,6850.0%0.00%0.0%
Q2 2023$199,656
-9.5%
7,6850.0%0.00%
-50.0%
Q1 2023$220,714
-3.0%
7,6850.0%0.00%0.0%
Q4 2022$227,476
+12.0%
7,685
-9.9%
0.00%0.0%
Q3 2022$203,014
+6.6%
8,5300.0%0.00%0.0%
Q2 2022$190,390
-11.1%
8,5300.0%0.00%
+100.0%
Q1 2022$214,188
+20.8%
8,530
+72.4%
0.00%
-50.0%
Q4 2021$177,287
-41.2%
4,948
-30.2%
0.00%
-33.3%
Q3 2021$301,623
-1.7%
7,0870.0%0.00%0.0%
Q2 2021$306,796
+6.1%
7,0870.0%0.00%0.0%
Q1 2021$289,079
-9.9%
7,0870.0%0.00%0.0%
Q4 2020$320,758
+27.9%
7,0870.0%0.00%0.0%
Q3 2020$250,809
-6.2%
7,0870.0%0.00%0.0%
Q2 2020$267,393
+30.5%
7,0870.0%0.00%0.0%
Q1 2020$204,885
-44.2%
7,0870.0%0.00%
-25.0%
Q4 2019$367,461
-5.5%
7,0870.0%0.00%0.0%
Q3 2019$389,005
+35.1%
7,0870.0%0.00%
+33.3%
Q2 2019$287,874
+34.3%
7,0870.0%0.00%
+50.0%
Q1 2019$214,311
-10.0%
7,0870.0%0.00%
-33.3%
Q4 2018$238,194
-20.3%
7,0870.0%0.00%0.0%
Q3 2018$298,930
+31.7%
7,0870.0%0.00%0.0%
Q2 2018$227,000
-35.5%
7,0870.0%0.00%
-25.0%
Q1 2018$352,000
-7.9%
7,0870.0%0.00%0.0%
Q4 2017$382,0007,0870.00%
Other shareholders
ANIKA THERAPEUTICS INC shareholders Q2 2018
NameSharesValueWeighting ↓
Caligan Partners LP 591,675$17,513,58014.58%
Trigran Investments, Inc. 1,564,541$46,310,4134.64%
DIKER MANAGEMENT LLC 22,458$664,7570.77%
Virtus Fund Advisers, LLC 3,490$103,3040.74%
Portolan Capital Management 207,900$6,153,8400.61%
Virtus Investment Advisers, Inc. 16,086$476,1460.32%
Ranger Investment Management 140,205$4,150,0680.31%
BOOTHBAY FUND MANAGEMENT, LLC 367,510$10,878,2960.25%
Riverwater Partners LLC 9,778$289,4290.25%
Legato Capital Management LLC 7,556$223,6580.04%
View complete list of ANIKA THERAPEUTICS INC shareholders